Valeant emerges as white knight for Afexa; Gedeon Richter, STADA ink biosim collaboration; AEterna reports successful Ph3;


 @FierceBiotech: Actelion drug macitentan flunks PhII but safety data bolsters confidence in blockbuster PhIII. News | Follow@FierceBiotech

 @JohnCFierce: The Guardian runs down a litany of biotech failures, challenges and ends on a quick 'up' note regarding collaborations.Piece | Follow @JohnCFierce

 @RyanMFierce: New facebook app "PiggyDemic," from scientists at Tel Aviv University, aims to simulate how viruses spread and mutate.Item | Follow @RyanMFierce

 @MaureenFierce: Adimab adds Novo, Biogen Idec to roster of antibody partners. Story | Follow @MaureenFierce


> Valeant Pharmaceuticals has emerged as a white knight for Afexa, bidding $76 million for the company, which is fending off a hostile takeover attempt by Paladin. Story

> Gedeon Richter and STADA Arzneimittel AG have agreed to collaborate on developing a pair of biosimilars for rituximab and trastuzumab. Report

> AEterna Zentaris says that a late-stage study provided promising results for its oral diagnostic test for adult growth hormone deficiency. Story

> Contract Pharmaceuticals in Buffalo is letting go 128 workers. Story


Pharma News

 @FiercePharma: Top drugmakers report payments of $150M to 165K docs so far this year, FT finds. Last full year: $437M. Report | Follow@FiercePharma


> FT: Pharma payments to U.S. docs hit $150M. Report

> Public Citizen: FDA should change generics labeling rules. Article

> ESC backs AZ drug over Plavix on mortality benefit. News

> Docs blame reimbursement, complexity, cost-benefit for Provenge uptake. Story

Biotech Research News

> JHU researchers have a full platelet of blood-clotting research. More

> Researchers find new clues into spread of influenza B. News

> A possible solution found for TTR-related amyloid diseases. Report

> So, a needle-pulling-thread is outdated, doc goes sutureless. Article

> Patient in stem-cell treatment for MS reports improvement. Details

> Researchers dream up a new cause for narcolepsy. Story

Manufacturing News

> Sabotage suspected in U.K. painkiller case. News

> Distributor plans to excise supply chain links. Story

> WHO committee report keeps pharma current. Brief

> Abbott taps manufacturing smarts in Haiti rebuild. Details

> Venus warning letter belies poor 483 response. Article

> Time to put the innovation into manufacturing. More

> U.S. tax reform or not, offshore beckons. Report


And Finally... A U.N. group is warning of a possible resurgence of bird flu after a mutant strain was spotted in Asia. Currently used vaccines evidently can't protect people from this new version of avian flu. Story

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."